Adherex Technologies (ADHXF) 0.8930 $ADHXF
Adherex Technologies Inc. Announces Warrant Exchange
Marketwire - Mon Jun 30, 7:31AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF) (the "Company"
today announced it is offering holders of warrants originally issued by the Company on or about April 30, 2010 and March 29, 2011 the opportunity to exchange 180 warrants for one new warrant to purchase one share of common stock at a lower exercise price. Each 18 warrants eligible to participate in the exchange currently entitle the holder thereof to purchase one share of the Company's common stock at an exercise price of CAD$1.44. The new warrants issued in the exchange will entitle the holder thereof to purchase one share of the Company's common stock at an exercise price of US$0.50. Other than described above, the new warrants will have the same terms (including the same expiration date) as the warrants that are exchanged. The offer to exchange eligible warrants for new warrants will expire on July 29, 2014, unless extended to a later date by the Company. Some of the warrants eligible to participate in the exchange are listed on the Toronto Stock Exchange and trade under the symbol AHX.WT. The Company does not intend to list the new warrants on any securities exchange.
Adherex Announces Results From Two Sodium Thiosulfate Phase 3 Studies Presented at the 50th American Society of Clinical Oncology (ASCO) Meeting
Marketwire - Mon Jun 02, 5:01AM CDT
Adherex Technologies, Inc. (TSX: AHX)(OTCQB: ADHXF) today announced the results on the two Sodium Thiosulfate (STS) Phase III studies presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
Adherex Announces Results of Annual and Special Meeting
Marketwire - Fri May 30, 7:48AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF) today announced that the nominees listed in the management proxy circular dated April 28,2014 (the "Circular" for the Annual and Special Meeting of Shareholders were elected as directors of the Company at the Annual and Special Meeting of Shareholders held in Durham, North Carolina on May 28, 2014 (the "Meeting" . Detailed results of the vote for the election of the slate of directors are set out below:
Adherex Technologies Sees Share Volume Shoot Through The Roof
ACCESSWIRE - Tue May 27, 3:18PM CDT
Adherex Technologies Inc. (OTCQB: ADHXF) saw its share volume skyrocket on May 27th with 627,393 shares exchanging hands, twelve times higher than its three month daily average volume of 50,914 shares.
Adherex Responds to Trading Activity
Marketwire - Tue May 27, 11:50AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF) is responding to a request from the Investment Industry Regulatory Organization of Canada on behalf of the Toronto Stock Exchange following recent trading activity. Ordinarily, the Company's policy is not to comment on rumors or speculation. Adherex is not aware of any undisclosed material changes or corporate developments to account for this activity. However, as previously disclosed by Adherex on May 15, 2014, David Freyer, DO, MS, Children's Hospital Los Angeles, COG ACCL0431 Study Chair, will present, "The Effects of Sodium Thiosulfate (STS) on Cisplatin-induced Hearing Loss: A Report from the Children's Oncology Group," in an oral presentation on June 1, 2014, at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. The European based SIOPEL 6 study, "A Multicenter Open Label Randomized Phase III Trial of the Efficacy of Sodium Thiosulfate in Reducing Ototoxicity in Patients Receiving Cisplatin Chemotherapy for Standard Risk Hepatoblastoma," has been accepted for the "trials in progress" poster session on June 2, 2014. Edward A. Neuwelt, M.D., Professor at Oregon Health & Science University, will present the poster on behalf of the SIOPEL 6 investigators and support team.
Adherex Provides Corporate Update and First Quarter Ended March 31, 2014 Financial Results
Marketwire - Thu May 15, 3:02PM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF) today reported its financial results and recent developments for the first quarter ended March 31, 2014. All amounts are in US dollars unless otherwise specified.
Adherex Provides Corporate Update and Fiscal Year Ended December 31, 2013 Financial Results
Marketwire - Mon Mar 31, 7:04AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF), today reported its financial results and recent developments for the year ended December 31, 2013. All amounts are in US dollars unless otherwise specified.
OTC Signal Daily Stock Watch - Adherex Technologies Inc. (OTCQB: ADHXF)
WorldStockWire - Thu Sep 12, 2:30AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Adherex Announces Corporate Update
Marketwire - Thu Aug 15, 6:01AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF) announced today that David Lieberman has resigned from the Board of Directors. Rosty Raykov, CEO and a director of Adherex, will assume the role of Chairman of the Board of Directors. Robert Andrade has resigned as Chief Financial Officer and a director of the Company. Krysia Lynes, who has solid accounting background and has worked for Adherex since July 2010, will assume the role of Chief Financial Officer on an interim basis.
Adherex Reports Recent Developments and Second Quarter June 30, 2013 Financial Results
Marketwire - Fri Aug 09, 6:01AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF), today reported its financial results and recent developments for the second quarter ended June 30, 2013. All amounts are in U.S. dollars unless otherwise specified.
Adherex Reports Feedback from the FDA from End of Phase 2 Meeting
Marketwire - Thu May 23, 8:07PM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF), today announced that it has received feedback from the FDA at an End-of-Phase 2 meeting held yesterday. During the FDA meeting, Adherex reviewed the opportunity that eniluracil offers to Metastatic Breast Cancer (MBC) patients who had rapid disease progression on capecitabine. Adherex proposed a small pivotal single arm clinical study addressing the special ability of eniluracil/5-FU/leucovorin to meet the medical needs of these patients. However, the agency strongly recommended that Adherex consider other larger clinical trial design alternatives for the future development of eniluracil in MBC. In light of the Company's limited resources, Adherex is taking the Agency's recommendations into consideration as it reviews the feasibility of these and other clinical options.
Adherex Reports Recent Developments and First Quarter March 31, 2013 Financial Results
Marketwire - Mon May 13, 6:01AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF), a biopharmaceutical company focused on the development of eniluracil and 5-fluorouracil, today reported its financial results and recent developments for the first quarter ended March 31, 2013. All amounts are in U.S. dollars unless otherwise specified.
Adherex Technologies Inc. Announces Warrant Exchange
Marketwire - Mon Jun 30, 7:31AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF) (the "Company"
today announced it is offering holders of warrants originally issued by the Company on or about April 30, 2010 and March 29, 2011 the opportunity to exchange 180 warrants for one new warrant to purchase one share of common stock at a lower exercise price. Each 18 warrants eligible to participate in the exchange currently entitle the holder thereof to purchase one share of the Company's common stock at an exercise price of CAD$1.44. The new warrants issued in the exchange will entitle the holder thereof to purchase one share of the Company's common stock at an exercise price of US$0.50. Other than described above, the new warrants will have the same terms (including the same expiration date) as the warrants that are exchanged. The offer to exchange eligible warrants for new warrants will expire on July 29, 2014, unless extended to a later date by the Company. Some of the warrants eligible to participate in the exchange are listed on the Toronto Stock Exchange and trade under the symbol AHX.WT. The Company does not intend to list the new warrants on any securities exchange. Adherex Announces Results From Two Sodium Thiosulfate Phase 3 Studies Presented at the 50th American Society of Clinical Oncology (ASCO) Meeting
Marketwire - Mon Jun 02, 5:01AM CDT
Adherex Technologies, Inc. (TSX: AHX)(OTCQB: ADHXF) today announced the results on the two Sodium Thiosulfate (STS) Phase III studies presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
Adherex Announces Results of Annual and Special Meeting
Marketwire - Fri May 30, 7:48AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF) today announced that the nominees listed in the management proxy circular dated April 28,2014 (the "Circular"
for the Annual and Special Meeting of Shareholders were elected as directors of the Company at the Annual and Special Meeting of Shareholders held in Durham, North Carolina on May 28, 2014 (the "Meeting" . Detailed results of the vote for the election of the slate of directors are set out below: Adherex Technologies Sees Share Volume Shoot Through The Roof
ACCESSWIRE - Tue May 27, 3:18PM CDT
Adherex Technologies Inc. (OTCQB: ADHXF) saw its share volume skyrocket on May 27th with 627,393 shares exchanging hands, twelve times higher than its three month daily average volume of 50,914 shares.
Adherex Responds to Trading Activity
Marketwire - Tue May 27, 11:50AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF) is responding to a request from the Investment Industry Regulatory Organization of Canada on behalf of the Toronto Stock Exchange following recent trading activity. Ordinarily, the Company's policy is not to comment on rumors or speculation. Adherex is not aware of any undisclosed material changes or corporate developments to account for this activity. However, as previously disclosed by Adherex on May 15, 2014, David Freyer, DO, MS, Children's Hospital Los Angeles, COG ACCL0431 Study Chair, will present, "The Effects of Sodium Thiosulfate (STS) on Cisplatin-induced Hearing Loss: A Report from the Children's Oncology Group," in an oral presentation on June 1, 2014, at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. The European based SIOPEL 6 study, "A Multicenter Open Label Randomized Phase III Trial of the Efficacy of Sodium Thiosulfate in Reducing Ototoxicity in Patients Receiving Cisplatin Chemotherapy for Standard Risk Hepatoblastoma," has been accepted for the "trials in progress" poster session on June 2, 2014. Edward A. Neuwelt, M.D., Professor at Oregon Health & Science University, will present the poster on behalf of the SIOPEL 6 investigators and support team.
Adherex Provides Corporate Update and First Quarter Ended March 31, 2014 Financial Results
Marketwire - Thu May 15, 3:02PM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF) today reported its financial results and recent developments for the first quarter ended March 31, 2014. All amounts are in US dollars unless otherwise specified.
Adherex Provides Corporate Update and Fiscal Year Ended December 31, 2013 Financial Results
Marketwire - Mon Mar 31, 7:04AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF), today reported its financial results and recent developments for the year ended December 31, 2013. All amounts are in US dollars unless otherwise specified.
OTC Signal Daily Stock Watch - Adherex Technologies Inc. (OTCQB: ADHXF)
WorldStockWire - Thu Sep 12, 2:30AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Adherex Announces Corporate Update
Marketwire - Thu Aug 15, 6:01AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF) announced today that David Lieberman has resigned from the Board of Directors. Rosty Raykov, CEO and a director of Adherex, will assume the role of Chairman of the Board of Directors. Robert Andrade has resigned as Chief Financial Officer and a director of the Company. Krysia Lynes, who has solid accounting background and has worked for Adherex since July 2010, will assume the role of Chief Financial Officer on an interim basis.
Adherex Reports Recent Developments and Second Quarter June 30, 2013 Financial Results
Marketwire - Fri Aug 09, 6:01AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF), today reported its financial results and recent developments for the second quarter ended June 30, 2013. All amounts are in U.S. dollars unless otherwise specified.
Adherex Reports Feedback from the FDA from End of Phase 2 Meeting
Marketwire - Thu May 23, 8:07PM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF), today announced that it has received feedback from the FDA at an End-of-Phase 2 meeting held yesterday. During the FDA meeting, Adherex reviewed the opportunity that eniluracil offers to Metastatic Breast Cancer (MBC) patients who had rapid disease progression on capecitabine. Adherex proposed a small pivotal single arm clinical study addressing the special ability of eniluracil/5-FU/leucovorin to meet the medical needs of these patients. However, the agency strongly recommended that Adherex consider other larger clinical trial design alternatives for the future development of eniluracil in MBC. In light of the Company's limited resources, Adherex is taking the Agency's recommendations into consideration as it reviews the feasibility of these and other clinical options.
Adherex Reports Recent Developments and First Quarter March 31, 2013 Financial Results
Marketwire - Mon May 13, 6:01AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF), a biopharmaceutical company focused on the development of eniluracil and 5-fluorouracil, today reported its financial results and recent developments for the first quarter ended March 31, 2013. All amounts are in U.S. dollars unless otherwise specified.
